A Study of Quintuple Therapy to Treat COVID-19 Infection

Completed · Phase 2 · Has a placebo group

Conditions studied: COVID-19, Corona Virus Infection, Coronavirus-19, Sars-CoV2

In brief

This is a Phase II interventional study will test the efficacy of quintuple therapy (Hydroxychloroquine, Azithromycin, Vitamin C, Vitamin D, and Zinc) in the treatment of patients with COVID-19 infection).

Key facts

Study ID

NCT04334512

Run by

ProgenaBiome

People needed

118

Starts

2020-06-22

Expected to finish

2024-02-27

Last updated by the study team

2024-02-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Refusal to provide informed consent
• Diarrhea prior to infection
• Any comorbidities which, in the opinion of the investigator, constitute health risk for the subject
• Any contraindications for treatment with hydroxychloroquine
• Hypoglycemia
• Known G6PD deficiency
• Porphyria
• Anemia
• Neutropenia
• Alcoholism
• Myasthenia gravis
• Skeletal muscle disorders
• Maculopathy
• Changes in visual field
• Liver disease
• Psoriasis
• Anemia from pyruvate kinase and G6PD deficiencies
• Abnormal EKG with QT prolongation acquired or from birth
• Allergies to 4-Aminoquinolines
• History of jaundice or high fevers prior to developing COVID-19
• Treatment with any of the medications listed in Appendix II
• Treatment with any other drug not listed that affects the QT interval
• Treatment with any anti-epileptic drug, whether prescribed for seizures or otherwise.
• Pregnant or breastfeeding women

Where it is running

• ProgenaBiome — Ventura, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.